FIELD: medicine.
SUBSTANCE: claimed invention relates to pharmaceutical medicinal forms, which are applied for controlled and/or directed delivery of active substance to definite part of gastrointestinal tract of human or animals. Pharmaceutical medicinal forms preferably include active substance N-(2-(2-phthalimidoetoxy)acetyl)-L-alanyl-D-glutamic acid (LK 423).
EFFECT: also described are methods of treating chronic inflammatory diseases of gastrointestinal tract of human and/or animals applying pharmaceutical medicinal forms of claimed invention.
21 cl, 5 ex, 3 tbl, 7 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREPARATION OF PHARMACEUTICAL DOSAGE FORMS BASED ON METHYL METHACRYLATE COPOLYMERS | 2020 |
|
RU2747401C1 |
| MEDICINAL CONTROLLED-RELEASING FORMS OF AZITHROMYCIN | 1995 |
|
RU2130311C1 |
| METHODS OF TREATING GASTROINTESTINAL TRACT DISORDERS INDEPENDENTLY ON FOOD CONSUMPTION | 2014 |
|
RU2563993C1 |
| FORMULATIONS FOR ORAL DELIVERY OF ADSORBENTS IN INTESTINE | 2016 |
|
RU2681315C2 |
| PHARMACEUTICAL OR NUTRACEUTICAL COMPOSITION | 2010 |
|
RU2604861C2 |
| THE PHARMACEUTICAL COMPOSITIONS CONTAINING pH - DEPENDENT MEDICAL PRODUCT, THE pH MODIFIER AND THE SLOWING DOWN AGENT | 2006 |
|
RU2442574C2 |
| DOSAGE FORM IN CAPSULE FORM CONTAINING TABLETS WITH DIMETHYL FUMARATE | 2019 |
|
RU2742745C1 |
| PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLU5) ANTAGONISTS | 2011 |
|
RU2602955C2 |
| CHRONOTHERAPEUTIC PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2571067C2 |
| SYNERGETIC ANALGETIC COMBINATION OF OPIOID ANALGETIC AGENT AND CYCLOOXYGENASE-2 INHIBITOR | 1998 |
|
RU2232600C2 |
